Literature DB >> 6200801

Altered serotonin metabolism in depressed patients with parkinson's disease.

R Mayeux, Y Stern, L Cote, J B Williams.   

Abstract

Depression is a common symptom in patients with Parkinson's disease. It is not related to the severity of the motor symptoms or changes in dopamine metabolism and does not improve on treatment with dopamine agonists. Alterations in serotonin metabolism are found in primary (endogenous) depression. The brain content of serotonin in Parkinson's disease is also reduced, but this has not been related to any manifestation of the disorder. We found that the CSF content of the major metabolite of serotonin, 5-hydroxyindoleacetic acid, was lower in depressed than in nondepressed parkinsonians. The data suggest that the alterations in serotonin metabolism in Parkinson's disease identify a subgroup of patients who are prone to depression.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6200801     DOI: 10.1212/wnl.34.5.642

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  48 in total

1.  Mood and motor trajectories in Parkinson's disease: multivariate latent growth curve modeling.

Authors:  Laura B Zahodne; Michael Marsiske; Michael S Okun; Ramon L Rodriguez; Irene Malaty; Dawn Bowers
Journal:  Neuropsychology       Date:  2011-12-05       Impact factor: 3.295

Review 2.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

Review 3.  Stress, depression and Parkinson's disease.

Authors:  Ann M Hemmerle; James P Herman; Kim B Seroogy
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

4.  Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study.

Authors:  Daniel Weintraub; Donna Taraborelli; Knashawn H Morales; John E Duda; Ira R Katz; Matthew B Stern
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2006       Impact factor: 2.198

5.  Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression.

Authors:  Sven Pålhagen; Hongshi Qi; Björn Mårtensson; Jan Wålinder; Ann-Kathrine Granérus; Per Svenningsson
Journal:  J Neurol       Date:  2009-10-21       Impact factor: 4.849

6.  Cognitive functioning after pallidotomy for refractory Parkinson's disease.

Authors:  K Perrine; M Dogali; E Fazzini; D Sterio; E Kolodny; D Eidelberg; O Devinsky; A Beric
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

Review 7.  Neuropsychological aspects of Parkinson's disease.

Authors:  S A Raskin; J C Borod; J Tweedy
Journal:  Neuropsychol Rev       Date:  1990-09       Impact factor: 7.444

Review 8.  Parkinson's disease.

Authors:  E C Wolters; D B Calne
Journal:  CMAJ       Date:  1989-03-01       Impact factor: 8.262

Review 9.  Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.

Authors:  P Mourilhe; P E Stokes
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

10.  Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.

Authors:  R Cantello; M Aguggia; M Gilli; M Delsedime; I Chiardò Cutin; A Riccio; R Mutani
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.